Akèy › Kansè Endomèt › Minnesota › Minneapolis
Etid klinik pou Kansè Endomèt nan Minneapolis, MN
18 etid pou Kansè Endomèt ap chèche patisipan nan sit nan ak bò kote Minneapolis (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Ap rekriteFaz 2
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi lwen
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Ap rekriteFaz 3
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi lwen
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 2
- Health Partners Frauenshuh Cancer Center, Saint Louis Park · 5 mi lwen
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Ap rekriteFaz 2
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi lwen
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Ap rekriteFaz 3
- Minnesota Oncology Hematology, PA ( Site 8003), Minneapolis
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Ap rekriteFaz 3
- USOR - Minnesota Oncology/ Minneapolis Clinic, Minneapolis
- USOR - Minnesota Oncology, Minneapolis
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Ap rekriteFaz 3
- Research Site, Minneapolis
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- University of Minnesota Masonic Cancer Center, Minneapolis
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Ap rekriteFaz 1
- University of Minnesota, Minneapolis
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Ap rekriteFaz 1/2
- University of Minnesota/Masonic Cancer Center, Minneapolis
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Ap rekriteFaz 1
- Normunity Investigational Site, Minneapolis
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- M Health Fairview University of Minnesota Medical Center, Minneapolis
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Ap rekriteFaz 1/2
- M Health Fairview University of Minnesota Medical Center, Minneapolis
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Ap rekriteFaz 3
- Research Site, Minneapolis
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Ap rekriteFaz 2
- 518, Minneapolis
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
Ap rekriteFaz 1
- University of Minnesota, Minneapolis
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Allina Health Cancer Institute, Minneapolis
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
Ap rekriteFaz 2/3
- Minnesota Oncology Hematology, P.A., Minneapolis
Etid Kansè Endomèt nan lòt vil
- Houston, TX68 etid
- New York City, NY52 etid
- Boston, MA50 etid
- Arlington, VA39 etid
- Nashville, TN38 etid
- Los Angeles, CA34 etid
- St. Louis, MO29 etid
- Philadelphia, PA28 etid
- San Antonio, TX27 etid
- Queens, NY25 etid
- Columbus, OH25 etid
- Chicago, IL25 etid
Lòt etid nan Minneapolis
- Kansè nan tete27 etid
- Kansè Poumon ki pa ti selil26 etid
- Kansè ovè24 etid
- Kansè pwostat23 etid
- Kansè (tout kalite)22 etid
- Ensifizyans kadyak21 etid
- Kansè poumon20 etid
- Leksemi mieloïd egi20 etid
- Kansè kolorektal19 etid
- Maladi Parkinson17 etid
- Maladi kadyovaskilè15 etid
- Maladi atè koronè13 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.